ZUM VERHALTEN DES ERYTHROPOETINS BEI AREGENERATORISCHEN BLUTBILDUNGSSTOERUNGEN UNTER THERAPIE MIT ANABOLEN STEROIDEN = TAUX D'ERYTHROPOIETINE DANS LES MALADIES HEMATOLOGIQUES DEGENERATIVES TRAITEES PAR DES STEROIDES ANABOLISANTSNEUMANN E; HONETZ N; WURM B et al.1974; BLUT; DTSCH.; DA. 1974; VOL. 29; NO 6; PP. 373-381; ABS. ANGL.; BIBL. 25REF.Article

Treatment decision for stage I non-seminomatous germ cell tumours based on the risk factor vascular invasionHOELTL, W; PONT, J; KOSAK, D et al.British journal of urology (Print). 1992, Vol 69, Num 1, pp 83-87, issn 0007-1331Article

Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infectionPONT, J; PUCHHAMMER-STÖCKI, E; CHOTT, A et al.British journal of haematology. 1992, Vol 80, Num 2, pp 160-165, issn 0007-1048Article

Testicular cancer: prognostic implications of vascular invasionHOELTL, W; KOSAK, D; PONT, J et al.The Journal of urology. 1987, Vol 137, Num 4, pp 683-685, issn 0022-5347Article

CHOP-firstline treatment in NHL with unfavorable prognosis. Evaluation of therapeutic response and factors influencing prognosisHEINZ, R; NEUMANN, E; DITTRICH, C et al.Blut. 1985, Vol 50, Num 5, pp 267-276, issn 0006-5242Article